Focus: HCW Biologics is a public immunotherapy biotech focused on oncology and dermatology with an extremely early-stage pipeline. The company is pre-revenue with minimal commercial presence, operating as a research-driven entity.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow HCW Biologics to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for HCW Biologics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from HCW Biologics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session Benzinga
HCW Biologics Grants Exclusive Worldwide License for HCW11-006 to Trimmune with $7M Upfront Payment and Future Royalties 1 - Minichart
HCW Biologics Grants Exclusive Worldwide License for HCW11-006 to Trimmune with $7M Upfront Payment and Future Royalties 1 Minichart
12 Health Care Stocks Moving In Monday's Intraday Session - Acurx Pharmaceuticals (NASDAQ:ACXP), Axe Comp - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Acurx Pharmaceuticals (NASDAQ:ACXP), Axe Comp Benzinga
Nasdaq panel puts HCW Biologics back in full compliance to raise drug funding - Stock Titan
Nasdaq panel puts HCW Biologics back in full compliance to raise drug funding Stock Titan
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight - PR Newswire
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight PR Newswire
Inside HCW Biologics’ $7M deal to test a new cancer drug in China - Stock Titan
Inside HCW Biologics’ $7M deal to test a new cancer drug in China Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo